Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Evaluate Weight-Based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
This study has been completed.
Study NCT00585182   Information provided by University of Utah
First Received: December 21, 2007   Last Updated: June 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Obesity
Venous Thrombosis
Anticoagulants
Additional conditions recognized in this trial
Thrombosis
More general conditions related to this trial
Body Weight
Cardiovascular Diseases
Embolism and Thrombosis
Nutrition Disorders
Overnutrition
Overweight
Signs and Symptoms
Vascular Diseases
Interventions listed in this trial
Enoxaparin 0.5 mg/kg once daily
Additional drug interventions recognized in this trial
Enoxaparin
More general drug interventions related to this trial
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University of Utah
Sanofi-Aventis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services